Monopar Therapeutics Inc.MNPRNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+27.1%
5Y CAGR+27.1%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+27.1%/yr
vs +32.7%/yr prior
5Y CAGR
+27.1%/yr
Consistent
Acceleration
-5.6pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.3x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$21.62M+33.8%
2024$16.16M+83.0%
2023$8.83M-16.2%
2022$10.54M+15.4%
2021$9.13M+40.2%
2020$6.51M+50.5%
2019$4.32M+27.1%
2018$3.40M-79.5%
2017$16.60M+1291.9%
2016$1.19M-